05.06.25 -- Cutting Costs In Cell & Gene Therapy? Read This First.

We know how tough it can be to find the right CDMO, especially when capacity is tight and timelines are critical. That's why you’ll find our collection of recent Outsourced Pharma Capacity Update presentations so valuable. Our April Partners Week Update details the latest capabilities and available capacity from 40 leading CDMOs – and you can experience it all from the convenience of your screen. View the on-demand sessions for the modalities that fit your needs.

Review contract manufacturing's evolution, driven by technological advancements and regulatory changes, and how CMOs and CDMOs are navigating opportunities and challenges.

Developers often aim to cut expenses during development. Discover the long-term outcomes of cost-effective measures like using RUO leukopaks compared to investing in high-quality GMP-grade vectors.

Cell and gene therapies offer transformative potential for treating complex diseases, but their manufacturing and global delivery face significant challenges.

The ability to produce billions of NK cells in a single production run represents a transformative shift in the economics and logistics of cell therapy.

This panel session features a decade-long story of partnership in bringing two life-changing gene therapies to market successfully in 2022.

Witness how preserving spatial molecular information and leveraging AI-driven spatial-omics can transform treatment prediction, patient stratification, and personalized medicine.

By investing in the establishment and maintenance of a high-quality master cell bank (MCB), therapeutic developers can set themselves up for long-term success and ensure supply chain sustainability.

This study presents the results of a Design of Experiment (DoE) approach to assess how these process parameters impact rAAV yield and quality.

LVV manufacturing processes remain a significant hurdle for sponsors. Check out the potential of a packaging and producing cell line platform designed to enhance LVV manufacturing.

Ensure seamless access to European clinical trials and markets with GMP-compliant logistics, regulatory support, and risk mitigation to protect the integrity of your advanced therapies.

Consider several gene editing technologies — TARGATT, Mad7, and Base Editing — and gain insights into their transformative applications in genetic engineering and therapeutic development.

Discover how CDMOs can help you achieve and maintain CMC compliance throughout the drug development lifecycle. Outsourced Pharma Live will explore how to leverage CDMO expertise in process optimization, documentation, and regulatory submissions. Learn practical strategies to align your CMC goals with CDMO capabilities to accelerate development and ensure successful drug launches. Registration is free thanks to the support of Curia.

Partner with ElevateBio BaseCamp to leverage the LentiPeak platform for high-quality, scalable lentiviral vector production and accelerate your cell and gene therapy development.

Take a look behind the scenes and hear firsthand about the commitment to patients and clients at Andelyn Biosciences.

A CDMO that manufactures nucleases at research and cGMP grades can eliminate the need for custom manufacturing runs, simplify the transition to clinical application, and reduce regulatory paperwork.

By combining disruptive technology platforms with unparalleled genomic medicine development expertise, we're positioned to accelerate the development of LNP formulations and drug products.

Leverage POSTmark to streamline your path from R&D to cGMP-scale AAV production, reducing time, costs, and risks with a fully mirrored, scalable platform.